Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Dig Dis Sci. 2018 Jul 13;63(11):3067–3073. doi: 10.1007/s10620-018-5202-5

Figure 2.

Figure 2.

Receiver operator curve (ROC) analysis for serum adalimumab concentrations during maintenance therapy stratifying patients with Crohn’s disease with and without biochemical (A), endoscopic (B) or histologic (C) remission.

AUC: area under the curve, CI: confidence intervals.